Biotech Values

[DewDiligence]

CDTX IPOs (upsized) 5.52M* shares @$16.00:

http://finance.yahoo.com/news/cidara-therapeutics-announces-pricing-initial-113000750.html

Cidara is a biotechnology company focused on the discovery, development and commercialization of novel anti-infectives for the treatment of diseases that are inadequately addressed by current standard-of-care therapies. Cidara's initial portfolio is comprised of a long-acting echinocandin antifungal product candidate, CD101 IV, and CD101 topical, for the treatment of serious fungal infections. In addition, Cidara has developed a proprietary immunotherapy platform, Cloudbreak, designed to create compounds that direct a patient's immune cells to attack and eliminate pathogens that cause infectious disease. Cidara is headquartered in San Diego, California.

See #msg-112682706 for CDTX’s roadshow webcast.

*Assuming exercise of underwriter's option.